Please assess the completion status of the following clinical trial:

Trial Title: Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* female, 45 to 80 years of age, in good general health~* postmenopausal ≥2 years, surgically or naturally~* body mass index less than or equal to 32 kg/m\^2 at screening~Exclusion Criteria:~* no use within 3 months prior, nor use for more than 1 month at any time within 6 months of: glucocorticoids, anabolic steroids, estrogens, selective estrogen-receptor modulators (SERMs), or estrogen-related drugs, progestins, calcitonin, vitamin D supplements (\>1200 IU per day), calcitriol, calcidiol, or alfacalcidol at any dose, any bisphosphonate. fluoride (≥10 mg/day), strontium (≥50 mg/day), parathyroid hormone, investigational bone active agents.~* allergic or abnormal reactions to bisphosphonates~* history of cancer within 5 years, excluding squamous and basal cell carcinoma with 6 month remission~* positive pregnancy test~* no depot injection \>10,000 IU vitamin D in previous 9 months.~* no history of GI disease that requires medication, or history of Crohn's disease, ulcerative colitis, diverticular disease, polyps, or surgery that could have changed GI structure or motility.~* no history of frequent diarrhea or constipation that requires regular laxative use.~* no history of alcohol or durg abuse, hyperparathyroidism, cancer previous 5 years, major surgery within 1 month prior to screening, diabetes, uncontrolled hypertension, cardiovascular, hepatic, renal or GI disease.~* no active hyperthyroidism, osteomalacia, use of anticonvulsant medication, or allergic reaction to bisphosphonates

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 150 mg (Type: ACTIVE_COMPARATOR): 150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
- 75 mg (Type: EXPERIMENTAL): 75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
- 100 mg (Type: EXPERIMENTAL): 100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).